MOA Life Plus Co. Ltd. 142760

KRX · South Korea · Health Technology

KRW 479.00-3.00 (-0.62%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

MOA Life Plus Co. Ltd. 142760

KRX · South Korea · Health Technology

KRW 479.00-3.00 (-0.62%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-75.95% · 6MFull-screen chart

Open KRW 481.00High KRW 494.00Low KRW 472.00Close KRW 479.00Volume 53.84K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: KRW 482.00
Day range: KRW 472.00 – KRW 494.00
52-week range: KRW 463.00 – KRW 3,788.00
Volume: 53.84K
Market cap: KRW 10.16B
Avg. volume (1Y): 335.55K

Performance

1 week

+1.70%

1 month

-29.46%

3 months

-41.15%

6 months

-77.36%

Year to date

-85.91%

1 year

-86.32%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Biotechnology
Country: South Korea
Exchange: KRX
Shares outstanding: 21.08M
Employees: 54
ISIN: KR7142760008
Beta: 0.04

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceMar 27, 2026

NorthStrive Biosciences Signs Licensing Agreement Amendment with MOA Life Plus [KOSDAQ: 142760] for Dual Myostatin Assets Targeting Muscle Preservation in Combination with GLP-1 Treatments

NEWPORT BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc.’s (NASDAQ: ELAB) (“PMGC,” “we,” or “our”) wholly owned subsidiary, NorthStrive Biosciences Inc. (“Northstrive Biosciences”), announced today a third amendment (“Amendment”) to its existing License Agreement with MOA Life Plus Co., Ltd., [KOSDAQ: 142760] a Korean biotechnology company (“MOA,” and such existing agreement, as amended, “License Agreement”) Northstrive Biosciences holds for EL-32 and EL-22. The Amendment upd

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.